vs
Side-by-side financial comparison of NextPlat Corp (NXPL) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
NextPlat Corp is the larger business by last-quarter revenue ($12.8M vs $9.1M, roughly 1.4× Protalix BioTherapeutics, Inc.). NextPlat Corp runs the higher net margin — -40.2% vs -60.3%, a 20.2% gap on every dollar of revenue. On growth, NextPlat Corp posted the faster year-over-year revenue change (-21.1% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-339.0K). Over the past eight quarters, Protalix BioTherapeutics, Inc.'s revenue compounded faster (-6.7% CAGR vs -14.4%).
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
NXPL vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.8M | $9.1M |
| Net Profit | $-5.1M | $-5.5M |
| Gross Margin | 14.3% | 49.4% |
| Operating Margin | -28.9% | -51.1% |
| Net Margin | -40.2% | -60.3% |
| Revenue YoY | -21.1% | -49.9% |
| Net Profit YoY | -70.6% | -184.8% |
| EPS (diluted) | — | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.8M | $9.1M | ||
| Q3 25 | $13.8M | $17.9M | ||
| Q2 25 | $13.2M | $15.7M | ||
| Q1 25 | $14.5M | $10.1M | ||
| Q4 24 | $16.2M | $18.2M | ||
| Q3 24 | $15.4M | $18.0M | ||
| Q2 24 | $17.0M | $13.5M | ||
| Q1 24 | $17.5M | — |
| Q4 25 | $-5.1M | $-5.5M | ||
| Q3 25 | $-2.2M | $2.4M | ||
| Q2 25 | $-1.8M | $164.0K | ||
| Q1 25 | $-1.3M | $-3.6M | ||
| Q4 24 | $-3.0M | $6.5M | ||
| Q3 24 | $-4.2M | $3.2M | ||
| Q2 24 | $-5.3M | $-2.2M | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | 14.3% | 49.4% | ||
| Q3 25 | 19.9% | 53.4% | ||
| Q2 25 | 21.8% | 62.5% | ||
| Q1 25 | 23.8% | 19.1% | ||
| Q4 24 | 16.8% | 78.7% | ||
| Q3 24 | 23.2% | 53.4% | ||
| Q2 24 | 34.5% | 29.8% | ||
| Q1 24 | 27.8% | — |
| Q4 25 | -28.9% | -51.1% | ||
| Q3 25 | -14.5% | 11.9% | ||
| Q2 25 | -13.8% | 7.5% | ||
| Q1 25 | -10.2% | -41.0% | ||
| Q4 24 | -14.1% | 39.6% | ||
| Q3 24 | -52.1% | 22.2% | ||
| Q2 24 | -64.1% | -18.0% | ||
| Q1 24 | -10.5% | — |
| Q4 25 | -40.2% | -60.3% | ||
| Q3 25 | -15.9% | 13.2% | ||
| Q2 25 | -13.5% | 1.0% | ||
| Q1 25 | -9.2% | -35.8% | ||
| Q4 24 | -18.6% | 35.6% | ||
| Q3 24 | -27.4% | 18.0% | ||
| Q2 24 | -31.3% | -16.4% | ||
| Q1 24 | -8.5% | — |
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $0.03 | ||
| Q2 25 | — | $0.00 | ||
| Q1 25 | $-0.05 | $-0.05 | ||
| Q4 24 | — | $0.10 | ||
| Q3 24 | $-0.22 | $0.03 | ||
| Q2 24 | — | $-0.03 | ||
| Q1 24 | $-0.08 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.7M | $14.7M |
| Total DebtLower is stronger | $1.3M | — |
| Stockholders' EquityBook value | $17.3M | $48.2M |
| Total Assets | $27.5M | $82.3M |
| Debt / EquityLower = less leverage | 0.07× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.7M | $14.7M | ||
| Q3 25 | $13.9M | $13.6M | ||
| Q2 25 | $16.6M | $17.9M | ||
| Q1 25 | $17.7M | $19.5M | ||
| Q4 24 | $20.0M | $19.8M | ||
| Q3 24 | $20.4M | $27.4M | ||
| Q2 24 | $24.9M | $23.4M | ||
| Q1 24 | $23.5M | — |
| Q4 25 | $1.3M | — | ||
| Q3 25 | $1.2M | — | ||
| Q2 25 | $1.2M | — | ||
| Q1 25 | $1.3M | — | ||
| Q4 24 | $1.4M | — | ||
| Q3 24 | $1.5M | — | ||
| Q2 24 | $1.3M | — | ||
| Q1 24 | $1.4M | — |
| Q4 25 | $17.3M | $48.2M | ||
| Q3 25 | $21.4M | $52.9M | ||
| Q2 25 | $23.5M | $49.9M | ||
| Q1 25 | $25.3M | $45.2M | ||
| Q4 24 | $27.3M | $43.2M | ||
| Q3 24 | $22.5M | $32.4M | ||
| Q2 24 | $26.5M | $28.6M | ||
| Q1 24 | $31.2M | — |
| Q4 25 | $27.5M | $82.3M | ||
| Q3 25 | $30.0M | $82.3M | ||
| Q2 25 | $31.0M | $78.5M | ||
| Q1 25 | $35.2M | $73.9M | ||
| Q4 24 | $37.1M | $73.4M | ||
| Q3 24 | $41.1M | $61.6M | ||
| Q2 24 | $51.5M | $91.5M | ||
| Q1 24 | $65.1M | — |
| Q4 25 | 0.07× | — | ||
| Q3 25 | 0.05× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.07× | — | ||
| Q2 24 | 0.05× | — | ||
| Q1 24 | 0.04× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-302.0K | $2.0M |
| Free Cash FlowOCF − Capex | $-339.0K | $1.6M |
| FCF MarginFCF / Revenue | -2.6% | 17.8% |
| Capex IntensityCapex / Revenue | 0.3% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-302.0K | $2.0M | ||
| Q3 25 | $-2.7M | $-3.7M | ||
| Q2 25 | $-1.0M | $-5.2M | ||
| Q1 25 | $-2.1M | $-5.1M | ||
| Q4 24 | $-476.0K | $4.0M | ||
| Q3 24 | $-4.6M | $4.1M | ||
| Q2 24 | $2.3M | $-3.6M | ||
| Q1 24 | $-2.7M | — |
| Q4 25 | $-339.0K | $1.6M | ||
| Q3 25 | — | $-4.2M | ||
| Q2 25 | $-1.1M | $-5.7M | ||
| Q1 25 | $-2.1M | $-5.4M | ||
| Q4 24 | $-508.0K | $3.6M | ||
| Q3 24 | $-4.7M | $4.0M | ||
| Q2 24 | $2.2M | $-3.8M | ||
| Q1 24 | $-2.7M | — |
| Q4 25 | -2.6% | 17.8% | ||
| Q3 25 | — | -23.7% | ||
| Q2 25 | -8.0% | -36.2% | ||
| Q1 25 | -14.3% | -53.0% | ||
| Q4 24 | -3.1% | 19.6% | ||
| Q3 24 | -30.6% | 22.4% | ||
| Q2 24 | 13.2% | -28.1% | ||
| Q1 24 | -15.7% | — |
| Q4 25 | 0.3% | 4.4% | ||
| Q3 25 | 0.0% | 2.8% | ||
| Q2 25 | 0.1% | 2.8% | ||
| Q1 25 | 0.2% | 3.0% | ||
| Q4 24 | 0.2% | 2.3% | ||
| Q3 24 | 0.6% | 0.5% | ||
| Q2 24 | 0.4% | 1.3% | ||
| Q1 24 | 0.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | — | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NXPL
| Healthcare Operations | $9.0M | 70% |
| Ecommerce Revenue | $3.8M | 30% |
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
